Forecast

The analysts' average price target is +1,72€ (+300,00%). The median is +1,72€ (+300,00%).

Buy	3
Hold	0
Sell	0

News Go to news feed

Vaxart reports favorable 12-month safety data for oral COVID vaccine, main cohort topline due H1 2027

Vaxart reported no vaccine-related serious complications in the 400-participant Phase II‑B Sentinel cohort of its oral COVID-19 vaccine and will seek BARDA approval to release top-line data from the ~5,000-participant main cohort in the first half of 2027. BARDA provided a $29 million contract modification to fund expanded safety, immunogenicity and genomic analyses, including mucosal antibody testing. The company ended Q2 2026 with $64 million in cash and short-term investments, sufficient to fund operations into Q2 2027 under the current plan, and continues to pursue a norovirus partnership while implementing board and governance changes. » More on finance.yahoo.com
Vaxart misses Q2 forecasts: revenue falls due to declining BARDA payments

Vaxart reported second-quarter revenue of $27.2 million (forecast $50.5 million) and a loss of $0.06 per share (forecast $0.03). Revenue declined 31.5% year over year, mainly due to lower BARDA contract payments, while reduced R&D spending lowered the net loss. The company has $64 million in cash and expects liquidity to last into Q2 2027. The main cohort of the COVID-19 study is fully recruited; initial efficacy and safety data are expected in the first half of 2027, and BARDA has provided an additional $29 million for expanded analyses. » More on de.investing.com
Vaxart investors reject say-on-pay — CEO says no reverse split planned for now

Shareholders re-elected Vaxart's full board and ratified its auditor but voted down the non-binding say-on-pay proposal at the 2026 annual meeting. CEO Steven Lo said the company is not pursuing a reverse stock split now and has no current plan for a special meeting, preferring to execute its strategy and seek organic stock-price improvement. Management highlighted progress in COVID-19 and norovirus programs, confirmed a cash runway into Q2 2027, and said it is pursuing non-dilutive funding and potential norovirus partnerships. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2012, Vaxart has already paid 57,38€ in dividends. The last payout was in November 2012.

Financials

In the last quarter, Vaxart had revenue of 23.82m€ and net profit of −11.82m€

(EUR)	Jun 2026	YoY
Revenue	+23.82m	29,33%
Gross profit	+23.82m	29,33%
Net profit	−11.82m	7,01%
EBITDA	−10.68m	4,04%

Fundamentals

Metric	Value
Market capitalization	+103.89m€
Number of shares	242.04m
52-week high/low	+0,72€ - +0,27€
Dividends	No
Beta	1,1
P/E ratio	+3,33
PEG ratio	+0,01
P/B ratio	+1,47
P/S ratio	+0,50

Company profile

Vaxart, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und beschäftigt sich mit der Entdeckung und Entwicklung von oralen rekombinanten Proteinimpfstoffen, die auf der firmeneigenen Schluckimpfstoff-Plattform basieren. Die Produktpipeline des Unternehmens umfasst einen Norovirus-Impfstoff, einen oralen Tablettenimpfstoff, der sich in einer klinischen Phase-Ib-Studie mit einem bivalenten oralen Tablettenimpfstoff für die Norovirus-Stämme GI.1 und GII.4 befindet; einen saisonalen Grippeimpfstoff, der sich in einer klinischen Phase-II-Studie zur Behandlung von H1-Infektionen befindet; einen Impfstoff gegen das Respiratorische Synzytialvirus und einen Coronavirus-Impfstoff, der sich in einer klinischen Phase-II-Studie zur Behandlung von SARS-CoV-2-Infektionen befindet. Außerdem entwickelt das Unternehmen therapeutische Impfstoffe gegen Gebärmutterhalskrebs und Dysplasie, die durch das humane Papillomavirus verursacht werden. Der Hauptsitz des Unternehmens befindet sich in South San Francisco, Kalifornien.